traded as nasdaq helsinki bth1v nasdaq biti industry biotechnology founded 1998 headquarters turku finland key people timo veromaa ceo peter fellner chairman of the board revenue 4.8 million 2012 1 operating income 25.6 million 2012 1 number of employees 38 end 2012 1 website biotie.com biotie therapies is a finnish biotechnology and pharmaceutics company . the company s research and development is focused on drugs for neurodegenerative and psychiatric disorders like parkinson s disease alzheimer s disease and other cognitive disorders alcohol and drug dependence and post traumatic stress disorder and inflammatory and fibrotic liver disease . the company s headquarters is in turku western finland and it is listed on nasdaq omx helsinki . contents 1 overview 2 product pipeline 2.1 selincro nalmefene 2.2 tozadenant 2.3 vap 1 2.4 nepicastat 2.5 ronomilast 3 references 4 external links overview edit biotie therapies was formed in the merger of biotie therapies corp. incorporated in 1998 2 oy contral pharma ltd and carbion inc in the year 2002 . in 2008 biotie therapies acquired the german pharmaceutical discovery and development company elbion gmbh in radebeul . in 2010 biotie therapies all preclinical assets were transferred into a new company biocrea gmbh in which biotie become a minority shareholder . in 2011 biotie acquired a pharmaceutical company synosia . 3 the company has partnering agreements with h. lundbeck a s and ucb . 4 5 product pipeline edit name target indications partner status selincro nalmefene alcohol dependence lundbeck eu marketing authorization received 6 tozadenant syn115 parkinson s disease ucb phase iii clinical trials to start 2015 7 vap 1 antibody inflammatory diseases phase i clinical trials ready seeking partner syn120 ad cognitive disorders phase i clinical trials ready seeking partner nepicastat syn117 ptsd cocaine dependency nida ptsd phase ii clinical trials results 8 cocaine dependency phase ii clinical trials in progress ronomilast copd phase i clinical trials ready seeking partner nitisinone syn118 movement disorder ucb phase ii clinical trials terminated 9 sources 10 selincro nalmefene edit the company s most advanced product nalmefene for the treatment of alcoholism . biotie s partner h. lundbeck a s received european marketing authorization from the european commission on 28 february 2013 . lundbeck expects to launch selincro in its first markets in middle of 2013 . 6 studies have shown that nalmefene has the ability to significantly limit both the patient s average alcohol intake and the number of days with an intake above five units of alcohol . the drug works by removing the patient s desire to drink more thereby controlling and limiting the intake of alcohol . the drug will be used in tablet form and taken only according to need . according to the company this is a novel approach for alcohol dependency treatment ; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time . 4 11 12 tozadenant edit syn115 also called tozadenant is developed for parkinson s disease . the product has a potential to be the first new treatment modality for the disease in more than 20 years . the product is an orally administered potent and selective inhibitor of the adenosine 2a receptor . it is being developed for the treatment of parkinson s disease but may also have potential for other cns disorders . 13 vap 1 edit vascular adhesion protein 1 vap 1 monoclonal antibody intended for treatment of inflammatory diseases is currently in phase i clinical trials with rheumatoid arthritis patients . according to the company inhibiting vap 1 reduces inflammation by regulating the migration of leukocytes or white blood cells to inflamed tissues . pathological accumulation of white blood cells in tissue is a common feature in many autoimmune diseases such as rheumatoid arthritis ulcerative colitis and psoriasis . 14 nepicastat edit syn117 also called nepicastat is a treatment for cocaine dependency and post traumatic stress disorder ptsd . it is orally administered potent and selective inhibitor of the enzyme dopamine hydroxylase dbh . 15 ronomilast edit ronomilast is a pde4 inhibitor for chronic inflammatory disorders . it is a small molecule phosphodiesterase 4 inhibitor pde4 . the product is developed for the treatment of chronic obstructive pulmonary disease copd . data from pre clinical and early clinical trials indicates that the product has a good safety profile . biotie is in the process of planning a phase 2 trial in copd patients and also seeking a partner for late stage development of ronomilast . 16 references edit a b c financial statements 2012 pdf . biotie therapies . retrieved 9 march 2013 . house douglas w. 5 june 2015 . biotie therapies on deck for u.s. debut . seeking alpha . biotie.com investors . february 2 2011 . a b biotie therapies oyj company description business week biotie.com collaborations . february 14 2013 . a b biotie selincro nalmefene receives european marketing authorization . 28 february 2013 . stock exchange release 27 february 2013 . 27 february 2013 . 1 stock exchange release 27 december 2012 2 stock exchange release 23 november 2011 biotie.com pipeline . february 14 2013 . lundbeck announces start of new phase iii clinical trials with nalmefene stock exchange release 15 december 2008 at 9.30 a.m balanced cns and inflammation product pipeline company website 2008 03 15 biotie.com syn115 tozadenant a highly differentiated product for parkinson s disease . march 26 2012 . interim report on biotie therapies corp. january 1 september 30 2008 biotie.com syn117 nepicastat for the treatment of cocaine dependency and post traumatic stress disorder ptsd . march 26 2012 . biotie.com ronomilast pde4 inhibitor for chronic inflammatory disorders . march 26 2012 . external links edit company s website retrieved from https en.wikipedia.org w index.php title biotie therapies & oldid 731970572 categories companies listed on the helsinki stock exchangepharmaceutical companies of finlandbiotechnology companiespharmaceutical companies established in 1988companies listed on nasdaqbiotechnology companies of finlandparkinson s disease navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages suomi edit links this page was last modified on 28 july 2016 at 18 38 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view